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Abstract
A new and improved method was developed for the determination and quantification of four Bfree^ thyroid hormones (i.e. 3,5-
diiodothyronine (T2), 3,3′,5-triiodothyronine (T3), 3,3′,5′-triiodothyrone (rT3) and 3,5,3′,5′-tetraiodothyronine (T4)) in human
serum by low- and high-resolution liquid chromatography-mass spectrometry (LC-MS). Several sample preparation strategies
were investigated to obtain matrix-independent results. These strategies included solid phase extraction and matrix dilution. The
developed analytical methods were then directly compared, in a blind study using patient-derived human blood serum samples, to
the current clinical routine testing methods, i.e. electrochemiluminescence immunoassay and enzyme-linked immunosorbent
assay. Chromatographic separation was achieved on a pentafluorophenyl (F5) column with an isocratic method of 30% aqueous
phase, 70% organic phase where mobile phase A is 0.1% formic acid in water (pH 4) and mobile phase B is 0.1% formic acid in
methanol (pH 4) (v/v). The high-resolution LC-MS was able to give a significant improvement in sensitivity with limits of
quantification of 0.002 to 0.008 pmol/L for all four Bfree^ thyroid hormones, as well as reduced sample preparation, making this
the preferred method. However, the increase in capital cost may be beyond the capabilities of some laboratories. The LC-MS
methods allow for the analysis of Bfree^ thyroid hormones to be carried out in a significantly reduced analysis time. Clinical
sample analysis showed that there was no statistical difference between the results obtained by ECLIA/ELISA and both LC-MS
methods.
Keywords Liquid chromatography-mass spectrometry . Immunoassays . Thyroid hormones . Serum . Quantitative analysis
Introduction
Thyroid compounds are a group of hormones responsible for
the regulation of a variety of biological functions, including
basal metabolic rate, lipid, glucose and carbohydrate metabo-
lism [1]. This group of compounds contains tyrosine-based
compounds including the physiologically active form triiodo-
thyronine (T3). The majority of triiodothyronine is formed
enzymatically by the deiodination of thyroxine (T4) [2, 3].
T4 can also be deiodinated to form an inactive form of T3
called reverse-triiodothyronine (rT3). Then, the physiological-
ly active T3 is further metabolised to form one of the isomers
of T2, i.e. 3,5-diiodothyroxine, prior to elimination from the
body (Fig. 1). Normal thyroid hormone reference intervals
have a large degree of variability based on a number of factors
including age, sex and ethnic origin of the population; the
range is calculated based on a 2.5th to 97.5th percentile of a
normal population with a seemingly healthy thyroid function
[4–6]. Within the Newcastle upon Tyne NHS Trust, the refer-
ence ranges are 3.5–6.5 pmol/L and 9.5–21.5 pmol/L for T3
and T4, respectively [7, 8].
There are two main medical conditions associated with
thyroid hormone levels: hyperthyroidism and hypothyroid-
ism. Hyperthyroidism is caused by an elevated level of triio-
dothyronine and is clinically indicated by a low thyroid-
stimulating hormone level and an elevated T4 and/or T3 con-
centration. Symptoms of which includes excessive weight
loss, heat intolerance, tremor, rapid heart rate and palpitations
and if left untreated can cause heart failure, osteoporosis, eye
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problems and miscarriage [9]. Hypothyroidism is caused by a
depleted level of triiodothyronine and is clinically indicated
by a high-normal thyroid-stimulating hormone level and a
depleted T4 level. Symptoms of which include inability to
lose weight and lack of energy [1, 10–13].
Currently, patient samples are analysed utilising
electrochemiluminescent immunoassay (ECLIA); howev-
er, each hormone must be detected separately with an anal-
ysis time of 18 min per hormone [14]. ECLIA uses
electrochemiluminescent labelled molecules, such as tris(2,2′-
bipyridyl)ruthenium(II) complex, which is repeatedly excited
with tripropilamine resulting in an amplification of the light
signal which is detected [14]. The sensitivity of this technique
also has an impact on the diagnosis and management of hypo-
thyroidism samples from hypothyroid patients as hormone
levels are often below the limits of quantification. Both of
which can cause significant problems when monitoring thyroid
hormone levels particularly in pregnant women [15–17]. The
method sheets supplied by the manufacturer state a permittable
error at the LOQ level of 30% has the potential to cause inac-
curacies in biological sample with lower thyroid level leading to
misleading results [18, 19]. Alternatively, research samples are
often analysed by enzyme-linked immunosorbent assay
(ELISA) due to unavailability of specialised instrumentation.
However, ELISA shows limited sensitivity for both thyroxine
and triiodothyronine [20, 21] and these limitations have led to a
number of studies into alternative analytical techniques. More
recent research have focused on utilising liquid chromatography
coupled to a mass spectrometer (LC-MS) in order to determine
a method for the simultaneous analysis of thyroid-stimulating
hormone (TSH), T4 and T3 [22–24]. One potential problem
with these methods is the separation of 3,5,3′-triiodothyronine
(T3) and 3,3′,5′-triiodothyronine (rT3), due to the high level of
structural similarity between the compounds. However, as rT3
is not physiologically active, it is necessary to be able to sepa-
rate the two compounds in order to obtain an accurate result [2].
A study found that rT3 and T3 can be separated when the MS
detector is operated in negative mode [25]. This is due to the
production of a difference in the mass spectrum produced for
the two compounds under negative ionisation MS/MS condi-
tions [25]. Allowing for monitoring of m/z 649.6, 632.5 and
522.9 for T3 and m/z 649.6, 632.5 and 478.5 for rT3 (see
Fig. 2 for an example MS fragmentation for T3) [26].
In addition, LC-MS instrumentation is becoming more
common place in clinical biochemistry laboratories: a tech-
nique whichwould lend itself well to the simultaneous analysis
of thyroid hormones while also reducing the analysis time. Due
to the structural similarities between the four compounds, par-
ticularly T3 and rT3, more sophisticated column chemistries
are required to give adequate resolution with a suitable run
time. It has been well reported that phenyl-based columns offer
an additional retention mechanism by introducing the possibil-
ity of π–π interactions. Pentafluorophenyl column have been
found to give increased resolution capacity with short run
times [27–30]. Acetonitrile has previously been found to im-
pede π–π interactions between the analytes and the phenyl
groups found on the stationary phase. Methanol, however,
has been shown to improve this selectivity [31] and is therefore
a most suitable organic modifier than acetonitrile when using
phenyl-based columns.
There are a number of papers documenting the develop-
ment and comparison of LC-MS methods for the analysis of
thyroid hormones, utilising positive ionisation. These include
the thyroid hormones T4 and/or T3 [32–34] as well as rT3 and
T2 [35]. Typical sample preparation extraction recoveries, for
the thyroid hormones, ranged between 62.7 and 114% with a
coefficient of variation of 1.8–31% and precision between 3.8
and 12% [35]. Correlation between LC-MS and immunoassay
methods, resulting in r2 values between 0.30 and 0.90
[32–35]. To be able to accurately measure T3 levels, in blood
serum, it is necessary to ensure that rT3 does not skew the
data. Therefore, rT3 is included within the method develop-
ment to ensure chromatographic separation. Advantageously,
both rT3 and T3 yield a different fragmentation pattern when
the mass spectrometer is operated in negative mode allowing
for the monitoring of different product ions [25]. In a similar
study, a comparison between LC-MS/MS and immunoassay-
based methods has been done on human serum, urine and
post-mortem blood for cannabinoids, opiates, amphetamines,
cocaine, benzodiazepines and methadone [36]. The developed
LC-MS/MS method [36] was considered to be an effective
screening method for forensic purposes in different matrices,
based on a simple protein precipitation strategy.
This paper investigates the simultaneous analysis of Bfree^
thyroid hormones using LC-MS in blood serum; Bfree^ thy-
roid hormones are defined as those that are not protein-bound
in the blood. Our analytical capabilities allow analysis of
Bfree^ thyroid hormones by low resolution, using an ion trap
mass spectrometer, and high resolution using an orbitrap mass
spectrometer. The results are compared, in a blind study, with
samples run using clinical routine testing methods based on
immunoassay (ECLIA and ELISA). The benefits of the LC-
MS approaches are compared.
Experimental
Chemicals and reagents
Standards of T4, T3, rT3 and T2 were purchased from Sigma-
Aldrich (Poole, Dorset) with a purity of ≥ 98%. Organic LC-
MS grade solvents, methanol, acetic acid and formic acid were
purchased from Sigma-Aldrich (Poole, Dorset). Hypersep™
C18 100 mg solid phase extraction (SPE) cartridges were
purchased from Thermo Fisher Scientific (Hemel
Hempstead, UK). Nylon 0.2 μm syringe filters were
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purchased from Thames Restek (High Wycombe, UK). Horse
serum was purchased from TCS Biosciences (Buckingham,
UK). Previously tested human blood serum samples were ob-
tained from the Royal Victoria Infirmary, North Tyneside
NHS trust. All biological samples were stored at − 80 °C prior
to analysis.
Instrumentation
For low-resolution LC-MS analysis, chromatographic separa-
tion was achieved using a Thermo Surveyor LC (Thermo
Scientific, Hemel Hempsted, UK) consisting of a quaternary
MS pump, vacuum degasser, a thermostated autosampler (set
to 5 °C) and a thermostated column oven (set to 25 °C). Mass
spectrometry was performed using a LTQ XL ion trap mass
spectrometer (Thermo Scientific, Hemel Hempsted, UK)
equipped with a heated electrospray ionisation (HESI) source
maintained at 200 °C. The solvent evaporation was aided with
auxiliary gas, sheath gas and sweep gas set to an arbitrary flow
rate of 15, 60 and 1, respectively. The mass spectrometer was
operated in selected reaction monitoring (SRM) MS/MS in
negative mode; collision energies and monitoring ions are
shown in Table 1. The monitored transitions were 776 →
604, 650→ 633, 650→ 479 and 524→507 for T4, T3, rT3
and T2, respectively. In SRMMS/MSmode, the precursor ion
is isolated and subjected to a specified amount of collision
energy to induce fragmentation. The MS method is then set
to monitor the precursor and a minimum of two stable product
ions. Chromatographic separation was achieved on a reversed
phase pentafluorophenyl column (Supelco 2.1 μm F5, 100 ×
2.1 mm) purchased from Sigma-Aldrich. Sample aliquots of
10 μL were introduced onto the column at a flow rate of
200 μL/min. The analytes were separated using water +
0.2% formic acid (A) and methanol + 0.2% formic acid (B)
as the mobile phase.
For high-resolution LC-MS analysis chromatographic sep-
aration was achieved using a Thermo Scientific ultimate 3000
LC (Thermo Scientific, Hemel Hempsted, UK) consisting of a
quaternaryMS pump, a thermostated autosampler (set to 5 °C)
and a thermostated column oven (set to 25 °C). Mass spec-
trometry was performed using a Q-Exactive hybrid orbitrap
mass spectrometer (Thermo Scientific, Hemel Hempsted,
UK) equipped with a heated electrospray ionisation (HESI)
source maintained at 200 °C. The solvent evaporation was
aided with auxiliary gas, sheath gas and sweep gas set to an
arbitrary flow rate of 15, 60 and 1, respectively. The mass
spectrometer was operated in SRMMS/MS in negative mode;
collision energies and monitoring ions are shown in Table 1.
Chromatographic separation was achieved on a reversed
phase pentafluorophenyl column (Supelco 2.1 μm F5, 100 ×
2.1 mm) purchased from Sigma-Aldrich. Sample aliquots of
10 μL were introduced onto the column at a flow rate of
200 μL/min. The analytes were separated using water +
0.2% formic acid (A) and methanol + 0.2% formic acid (B)
as the mobile phase.
Electrochemiluminescence immunoassay for both T3 and
T4 was performed using a Cobas e602 immunoassay analyser
(Roche Diagnostics Ltd., Burgess Hill, UK). All reagents were
purchased as an analysis kit from Roche Diagnostics Ltd.
(Burgess Hill, UK). A 15-μL aliquot of sample is analysed
via automated assay consisting of two incubation steps followed
by chemiluminescent emission measurement [18, 19].
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Fig. 1 Structures of thyroid hormones T4, T3, rT3 and a T2 isomer
Enzyme-linked immunosorbent assay for T3 and T4 was
performed using commercially available competitive ELISA
kits containing all reagent from Thermo Scientific (Hemel
Hempsted, UK) and measured using a BioTek microtitre plate
reader set to 450 nm (Swindon, UK). To a microcentrifuge
tube, 5 μL of sample and 5 μL of dissociation reagent were
added and vortexed gently prior to 5 min incubation at room
temperature and then 90 μL of 1× assay buffer was added.
Calibration standards were prepared as per the kit instructions.
To the appropriate wells, 10 μL of sample or standard was
added followed by 25 μL of conjugate and 25 μL of antibody.
The plate was then mixed and covered prior to 1 h incubation
at room temperature with shaking. Following incubation, the
solution was aspirated from each well and the wells were
washed four times with 300 μL of wash buffer, then 100 μL
of TMB substrate was added and incubated for further 30min.
To each well, 50 μL of stop solution was added and the plate
was read at 450 nm within 10 min [20, 21].
Preparation of stock solutions and samples
Stock solutions of each hormone were prepared at a concen-
tration of 0.5 mg/mL in methanol and aliquoted into 100 μL
aliquots and stored at − 20 °C. Calibration standards were
prepared daily for each analysis from the stock solution by
diluting in mobile phase (unless otherwise stated).
Calibration standards were prepared over a concentration
range of 0–257, 0–307 and 0–367 pmol/L for low-resolution
LC-MS and 0–129, 0–154 and 0–183 pmol/L for high-
resolution LC-MS for T4, T3/rT3 and T2 respectively. A full
set of calibration standards were ran at both the start and end
of each chromatographic run cycle. In addition, a quality
C15H8I3O4-
m/z 633
C15H11I3NO4
m/z 650
+ NH3
+ I-
+ HI
C15H11I2NO4-
m/z 523
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Fig. 2 Mass spectrum fragmentation for T3
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control standard was prepared at 50 pmol/L, by diluting stock
standard solutions in mobile phase and analysed at points
throughout the run to ensure there was no deviation through-
out the run. The concentration of the quality control was se-
lected as it is a mid-reference range for T4 [19].
Matrix-matched calibration standards for LOQ and LOD
determination were prepared in triplicate from the stock solu-
tion by diluting in horse serum and extracted by SPE.
Calibration standards were prepared over a concentration
range of 0.5–200 pmol/L for low-resolution LC-MS and
0.001–100 pmol/L for high-resolution LC-MS.
For low-resolution LC-MS serum samples were thawed
and vortexed prior to extraction. The final developed method
was applied to samples, prepared in triplicate, by transfer-
ring 500 μL to microcentrifuge tubes along with 500 μL
of 0.1% formic acid in water. Samples were vortexed and
centrifuged at 5300g for 5 min. The supernatants were
loaded onto a HyperSep™ C18 solid phase extraction
(SPE) cartridge, which were preconditioned sequentially
with 2 mL of 0.1% formic acid in methanol and 2 mL
0.1% formic acid in water. The cartridge was washed with
1 mL of 30% methanol in water and then the target com-
pounds were eluted with 1 mL of 80% methanol in water.
The eluent was dried down under a stream of nitrogen and
reconstituted in 50 μL of mobile phase.
For high-resolution LC-MS, serum samples were thawed
and vortexed prior to dilution. Samples were prepared by
transferring 10 μL of sample to an autosampler vial and dilut-
ed with 990 μL of water and vortex mixed.
Method validation
The developed method was validated in accordance with the
EMA guidelines [37]. Horse serumwas used as a blank matrix
due to having much lower levels of thyroid hormones than
human samples. With normal ranges of 0.00024–
0.00128 pmol/L and 0.0165–0.0244 pmol/L found in adult
horses compared with that of 3.1–6.8 pmol/L and 12–
22 pmol/L for adult humans for T3 and T4, respectively [18,
19, 38]. Furthermore, the levels in horse serum are below the
limit of detection for both the low- and high-resolution instru-
ments. Selectivity was determined by spiking thyroid hor-
mones into horse serum at a concentration of 50 pmol/L
followed by replicate analyses of blank horse serum. This
solution was extracted following both the low- and high-
resolution samples procedures and analysed in full scan mode
to identify any potentially interfering matrix components. To
access for any potential ion suppression or enhancement, thy-
roid hormones at low, mid and high concentrations were
spiked into extracted horse serum and compared against
T2
Monitored transions 524 → 507 m/z
T3
Monitored transions 650 → 633 m/z
rT3
Monitored transions 650 → 479 m/z
T4
Monitored transions 776 → 604 m/z
a
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Fig. 3 Chromatogram of the separation of Bfree^ thyroid hormones by
LC-MS. a Horse serum sample. Ions extracted at 507 m/z (top), 633 m/z
(second), 479 m/z (third) and 604 m/z (bottom). b Their associated mass
spectra
standard peak area. Linearity was determined by plotting peak
area against concentration. An r2 value of > 0.99 was deemed
to show linearity. Limits of detection (LOD) and quantifica-
tion (LOQ) was determined using replicate preparation of the
calibration curve. The slope of the curve and the standard
deviation of the intercept were used to calculate the LOD
and LOQ based on the following equations: LOD = 3.3σ/s
and LOQ = 10σ/s, where σ is standard deviation of intercept
and s is the slope [39]. Precision was determined by injection
of standards at the low, high and mid-point of the calibration
curve in triplicate, and the average is reported in Table 1 (stan-
dard precision). Intermediate precision was determined by re-
peating the precision analysis over the duration of the project
(3 months). Instrument precision was determined by
performing 20 injections from the same standard vial.
Matrix-matched precision was determined by the injection of
b
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replicate preparations from human serum samples (sample
precision). Stock solutions were aliquoted and stored at −
20 °C as recommended by the manufacturer. Solution stability
was performed by analysis of the stock standard solution
weekly for the first 3 months and then every 4 weeks in order
to determine maximum storage duration. Dilute solution were
also stored at 2–8 °C in order to access stability when placed
in the temperature-controlled autosampler. Dilute solutions
were analysed daily as the supplier information indicates a
storage stability of 7 days.
Extraction recoveries were determined by obtaining
peak area data for calibration standards at low, mid and
high calibration curve points. Thyroid hormones were
spiked into horse serum both pre- and post-extraction for
the low-resolution and pre- and post-dilution for high-
resolution LC-MS analyses. To calculate the % recovery,
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the peak area of the pre-extraction spiked samples was
divided by the peak area of the post-extraction spiked sam-
ples and multiplied by 100.
Results and discussion
Method development
Separation was obtained using a Supelco Ascentis Express™
F5 HPLC columnwithin a run time of 5 min utilising acidified
methanol and water as the mobile phase. The ability to sepa-
rate T3 and rT3 allows for reliable measurement of T3 in
serum samples; in order to do this, LC-MS parameters were
optimised utilising both the internal tuning parameters and
manual gas adjustment in order to achieve the optimum re-
sponse for the thyroid hormone. MS/MS fragmentation pa-
rameters were optimised by direct infusion of each thyroid
hormone and the adjustment of parameters until a precursor
ion of around 10% relative abundance and two stable product
ions were obtained (see for example, Fig. 3b). Horse serum
was used to determine specificity and extraction recoveries.
Horse blood was chosen as it poses a reduction in the patho-
genic risk while still containing the matrix material, of rele-
vance for Bfree^ thyroid hormone determination, which could
potentially interfere with the analysis.
The influence of the blood serum matrix was investigated
on the recovery of Bfree^ thyroid hormones using both low-
and high-resolution LC-MS. Initially, solid phase extraction
followed by low-resolution LC-MS sample volume was
investigated (Table 2). It was found that if the sample volume
was reduced from 1000 to 10 μL, little variation was deter-
mined in terms of recoveries from horse blood serum of the
four Bfree^ thyroid hormones. Then, subsequently using the
1000 μL horse blood serum sample, the influence of matrix
interferences were investigated by running calibration stan-
dards for T2, T3, rT3 and T4 in mobile phase and horse blood
serum and by spiking the previously extract horse serum with
standards at low, mid and high concentration levels. The re-
sults of the slopes of their respective calibration graph data are
shown in Table 3 and the peak area ratio are shown in Table 4.
No matrix effect was established when using solid phase ex-
traction followed by low-resolution LC-MS.
For high-resolution LC-MS, the influence of serial dilution
was investigated, based on a 20-pmol/L standard prepared
initially in mobile phase and subsequently serially diluted,
over five different serial dilutions, in horse blood serum
(Table 5). It was found that once the serial dilution equated
to a 1 in 100 dilution, no matrix effects were identified. Then,
subsequently using the 1 in 100 serial dilution in horse blood
serum sample, the influence of matrix interferences were fur-
ther investigated by running calibration standards for T2, T3,
rT3 and T4 in mobile phase and horse blood serum. The re-
sults of the slopes of their respective calibration graph data are
shown in Table 6. No matrix effect was established when
using serial dilution (1 in 100) followed by high-resolution
LC-MS.
Extracted ion chromatograms for the four Bfree^ thyroid
hormones in horse serum are shown in Fig. 3 along with their
respectivemass spectra. No interfering peaks were observed at
the same retention time as the compounds of interest, verify-
ing that the method was selective for the detection and quan-
tification of the four thyroid hormones. The calibration curves
showed a linear response across the standard range of 0–257,
0–307 and 0–367 pmol/L and 0–129, 0–154 and 0–
0183 pmol/L for low-resolution and high-resolution LC-MS,
respectively. This was determined by plotting peak area
against concentration and an r2 value of greater than 0.99
was deemed to be a linear response (Table 1). The method
also showed good precision for both repeat injections from
Table 3 Method development:
investigation of matrix effects in
horse blood serum using solid
phase extraction followed by low-
resolution LC-MS for Bfree^ thy-
roid hormone determination
Compound Linearitya in
mobile phase
y =mx + c
R2 value Linearitya in
blood serum
y =mx + c
R2 value Matrix effectb
(mobile phase:
horse serum)
T2 345x − 1154 0.9968 339x − 1739 0.9972 1.02
T3 335x − 1059 0.9951 323x − 1250 0.9986 1.04
rT3 332x − 1091 0.9962 345x − 1136 0.9971 0.96
T4 213x − 101 0.9966 209x − 29 0.9987 1.02
a Concentration range 0–200 pmol/L
bDetermined using the slope of the calibration graphs in mobile phase and horse blood serum
Table 2 Method development: investigation of sample volume
Sample volume (mL) Mean % recovery (n = 3) (%RSD)
T2 rT3 T3 T4
1 96.0 (3.8) 97.8 (2.5) 98.8 (0.7) 99.2 (0.4)
0.1 97.9 (3.7) 99.0 (3.6) 98.2 (0.6) 99.9 (0.2)
0.01 95.8 (3.8) 97.9 (1.8) 100.4 (0.6) 99.0 (1.5)
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one vial and replicate injections, with a % RSD of less than
5% for all low, medium and high standard concentrations as
well as matrix-matched preparations (Table 1).
Both the low- and high-resolution LC-MS methods
showed good sensitivity for all four thyroid hormone with a
LOQ for both standards and matrix-matched standards of be-
tween 0.17–5.87 and 0.002–0.006 pmol/L for low resolution
and high resolution, respectively (Table 1). The improvement
in sensitivity for T3 is of importance as it is found at lower
concentration within serum samples. In addition, the sensitiv-
ity of T3 using ECLIA and ELISA is close to the lower value
of the reference interval and therefore causes errors when de-
tecting this compound below the reference range. The sensi-
tivity for both LC-MS methods covers the expected ranges of
T3 and T4 and the pre-concentration step included in the SPE
method for low-resolution analysis allowed for low levels of
thyroid hormones to also be detected. It is also reported in the
ECLIA method sheets [17, 18] that there is a permittable error
of 30% at the limit of quantification for both T3 and T4 which
is not observed in either LC-MS method with a precision of
2.1 and 3.3% for low resolution and 1.8 and 3.9% for high
resolution for T4 and T3, respectively. The extraction recov-
eries for the SPE extraction method were assessed by spiking
a known standard concentration into horse blood serum sam-
ples and then extracting as per the sample preparation method
for low-resolution LC-MS. The extraction method was
assessed at low and high levels of thyroid hormones to ensure
consistence across a range of sample concentrations. The re-
coveries were 96.4% and 98.5% for the low concentration and
high concentration samples, respectively. Stock solution sta-
bility was accessed for all four thyroid hormones until such
time that the concentration obtained differed by ± 15% of the
nominal concentration. It was found that the stock solutions
were stable at − 20 °C for 52 weeks. The dilute solutions were
stable at 2–8 °C for 10 days ensuring stability of solutions
during analysis (Fig. 4).
Direct comparison of analytical methods using
hospital-derived blood serum samples
Human serum samples were provided by the Royal Victoria
Infirmary which had been previously tested for T4 and T3 and
were analysed, in a blind study, using the validated LC-MS
methods for both low-resolution and high-resolution LC-MS
(Electronic Supplementary Material (ESM) Table S1). The
analysis showed that the method for both low resolution and
Table 4 Method development:
investigation of ion matrix
suppression and enhancements in
horse blood serum by low-
resolution LC-MS for Bfree^ thy-
roid hormone determination
Compound Concentration (pmol/L) Peak area standard Peak area spiked
horse serum
Peak area ratio
T2 10 8016 7712 1.04
180 35,108 32,340 1.09
360 67,389 65,856 1.02
T3 10 7854 7382 1.06
150 30,971 30,171 1.03
300 68,985 63,705 1.08
rT3 10 8768 8735 1.00
150 34,351 31,300 1.10
300 69,290 67,835 1.02
T4 10 8571 8412 1.02
120 21,483 20,752 1.04
250 43,987 42,776 1.03
Table 5 Investigation of matrix
effects in horse blood serum:
influence of dilution factor
Solution Ratio to 20 pmol/L standard in mobile phase
T2 T3 rT3 T4
20 pmol/L standard in mobile phase 1.00 1.00 1.00 1.00
1 in 10 dilution in serum 1.37 2.33 1.37 1.49
1 in 20 dilution in serum 1.26 1.53 1.36 1.45
1 in 40 dilution in serum 1.19 1.23 1.34 1.26
1 in 60 dilution in serum 1.14 1.21 1.17 1.15
1 in 80 dilution in serum 1.10 0.98 1.12 1.08
1 in 100 dilution in serum 1.00 1.00 1.03 1.01
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Fig. 4 Stock solution stability for
solutions stored at a − 20 °C and b
2–8 °C
Table 6 Investigation of matrix
effects in horse blood serum using
a serial dilution of 1 in 100
followed by high-resolution LC-
MS
Compound Linearitya in
mobile phase
y =mx + c
R2 value Linearitya in
horse blood serum
y =mx + c
R2 value Matrix effectb
(mobile phase:
horse blood serum)
T2 210,547x − 90,945 0.9992 209,568x − 102,529 0.9996 1.00
T3 229,802x − 107,024 0.9993 226,213x − 99,456 0.9995 1.02
rT3 208,531x − 76,627 0.9956 205,189x − 126,705 0.9977 1.02
T4 229,796x − 109,230 0.9993 229,804x − 10,465 0.9993 1.00
a Concentration range 0–150 pmol/L
bDetermined using the slope of the calibration graphs in mobile phase and horse blood serum
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Fig. 5 Measurement agreement
plots for a T4 by ELISA or
ECLIA versus LC-MS and b T3
by ELISA or ECLIA versus LC-
MS. ECLIA, N = 118; ELISA,
N = 40; LR-LC-MS, N = 158;
HR-LC-MS, N = 158
Table 7 Statistical p values
between low and high-resolution
LC-MS and an immunoassay
method
Compound: technique Paired sample t test
All samples Sample concentration < 10 pmol/L
T4: ELISA v LR-LC-MS 0.069 0.330
T3: ELISA v LR-LC-MS 0.074 0.347
T4: ELISA v HR-LC-MS 0.137 0.334
T3: ELISA v HR-LC-MS 0.140 0.326
ELISA enzyme-linked immunosorbent assay (N = 40), LR-LC-MS low-resolution liquid chromatography-mass
spectrometry (N = 158), HR-LC-MS high-resolution liquid chromatography-mass spectrometry (N = 158)
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high resolution were comparable to the clinical routine testing
methods of ECLIA and the more readily available ELISA.
Figure 5 shows the measurement agreement analysis of each
method compared to the results obtained by LC-MS. The null
hypothesis for the statistical analysis is that the means of the
comparable methods for each hormone are the same. In order
to accept the null hypothesis at the 95% confidence interval, a
p value of > 0.05 should be obtained. Statistical paired sample
t test using SPSS found that there was no statistical different
between the means of each set of data at the 95% confidence
interval (Table 7). However, it was not possible to obtainmean
data for the ECLIA data as only a single clinical measurement
was made.
A comparison of all four methods (Table 8) shows a sig-
nificant reduction in analysis time for high-resolution LC-MS
and also batch analysis by low-resolution LC-MS from 20 to 7
and 8.75 min, respectively. Both LC-MS method are also able
to analyse all four hormones in one run, meaning that repeat
tests do not need to be performed for each hormone. However,
due to the SPE extraction used for low-resolution LC-MS, a
higher level of operator skill is required when compared with
the other three methods, which mainly require the operator to
be skilled in basic laboratory techniques and the use of spe-
cialist software. The increase in skill level and training re-
quirements may still be a more favourable option over the
high-resolution LC-MS for some laboratories due to the in-
crease in capital cost associated with the high-resolution
instrumentation.
The developed method reduces the run time from 14 to
5 min and as an isocratic method it removes the need for
column re-equilibration in between samples. The method also
shows improvements over those previously published in terms
of precision, extraction recoveries and correlation [32–35].
Tanoue et al. [35] reported extraction recoveries, for low con-
centration, 82.9, 81.9, 83.5 and 62.7% and for high concen-
tration, 86.9, 90.5, 90.0 and 69.6% for T4, T3, rT3 and T2,
respectively. They also reported [35] precision data with typ-
ical %CV ranging between 6.1 and 8.5% for T4 and 3.8 and
8.6% for T3. In this work, we report significantly higher ex-
traction recoveries of 97.9, 95.9, 98.2 and 99.7%, at low con-
centration, and 97.9, 95.8, 99.3 and 99.0%, at high concentra-
tion, for T4, T3, rT3 and T2, respectively. Precision also
showed improvements with %CVs of between 2.2–3.3 and
1.8–3.8 for low-resolution and high-resolution LC-MS instru-
ments, respectively (Table 1). Data previously published
[32–35] showed limited correlation between LC-MS and im-
munoassay methods. Typical reported correlation coefficients
of 0.67, 0.74 and 0.90 for T3 only at low, medium and high
concentrations, respectively [34]; 0.80 and 0.48 for T4 only in
samples from cats and dogs, respectively [35]; 0.37 and 0.53
for T3 and T4, respectively [32]; and 0.30 and 0.55 for T3 and
T4, respectively [33]. This newly reported method produced
data which showed good correlation (all > 0.99) compared to
the currently used immunoassay methods both across the full
concentration range and when focusing on low level samples
(Fig. 5).
Conclusion
LC-MS methods for the analysis of Bfree^ thyroid hormones
have been previously published; however, these have shown a
large variation in sample extraction recoveries and precision
data. Therefore, offering limited improvements on the current-
ly used ECLIA method. These papers also have limited com-
parison of new with existing established methodologies and
those which have included comparison show limited correla-
tion between the methods.
The developed LC-MS methods are able to identify and
quantify the four Bfree^ thyroid hormones with improved sen-
sitivity and accuracy for T3 and T4 compared to the methods
currently used within the NHS and research facilities. The
Table 8 Comparison of current and new methodologies
ECLIA ELISA Low-resolution LC-MS High-resolution LC-MS
Number of thyroid hormones analysed per run 1 1 4 4
Sample preparation technique Pipetting/dilution Pipetting/dilution SPE Pipetting/dilution
Operator skill Medium Low–medium Medium to high Medium
Automation Yes No No Yes
Sample preparation time, per sample (min) 2 2 Batch analysis 3.75; individual
analysis 30
2
Analysis time, per sample (min) 18 180a 5 5
Total time (min) 20 182 Batch analysis 8.75; individual
analysis 35
7
Approximate capital cost Medium Low Medium High
Typical cost per run Low High Low Low
Operator skill scale: low, basic laboratory skills; medium, use of specialised software; high, use of specialised laboratory skill
a 96-well plate capable of analysing 16 samples in triplicate
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developed LC-MS methods showed no statistical difference
when compared to the immunoassay methods. The LC-MS
methods have the added advantage of being able to analyse
all four Bfree^ thyroid hormones within one instrument run as
opposed to the need to run each thyroid hormone separately
when using both ECLIA and ELISA, therefore significantly
reducing the analysis time for both the low- and high-
resolution LC-MSmethods. Although not tested as part of this
study, automation could also be used by utilising autosampler
programing to perform sample dilution on the high-resolution
LC-MS method and the possibility of in-line SPE for the low-
resolution LC-MS method.
The high-resolution LC-MS method shows the greatest
improvement in terms of sensitivity and analysis time;
however, due to the increase in capital cost, this may be
less favourable in certain laboratories. Therefore the low-
resolution LC-MS method would be a useful compromise
as the increase in sensitivity and reduction in analysis time
would still be achievable but with a reduced capital expen-
diture. With both LC-MS methods, there would be a re-
quirement for staff training in the form of software training
and/or SPE training which would need to be factored into
expenditure costs.
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